Over 300 Texas Auctions End Today - Bid Now
Over 30 Total Lots Up For Auction at Two Locations - WI 05/27, NV 05/29

Dr. David Wong

Professor recognized for contributions to PET and Theranostics
September 12, 2018
Molecular Imaging PET
Dr. David Wong
NEWMARKET, Australia, Sept. 5, 2018 /PRNewswire/ -- Dr. David Chee Wong is a distinguished biographee of Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are chosen from among a pool of the most prominent professionals and are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Drawing upon more than three decades of professional experience, Associate Professor David Wong is presently the director of the Advanced PET and Nuclear Medicine Centre at Uniting Care Medical Imaging in Brisbane, Australia. In this position, he was instrumental involvement in the performance of the first Ga68 PSMA PET CT diagnostic imaging in men with prostate cancer on 16 July 2014 in Brisbane, Australia. Most recently in August 2017, David was involved in the first Lutetium 177 PSMA therapy in men with metastatic prostate cancer in Queensland, Australia.

A respected voice in the field of PET and radiology, David is an associate professor with the Centre of Advanced Imaging with the University of Queensland. Since the inception of his career, he has contributed numerous articles to professional journals pertaining to his areas of expertise. He was most recently credited as the co-author of "Flurodeoxyglucose Positron Emission Tomography May Be Helpful in the Case of Ductal Variant Prostate Cancer When Prostate Specific Membrane Antigen Ligand Positron Emission Tomography Scan is Negative," which was published in the Journal of Medical Imaging and Radiation Oncology in 2017. His other recent publications include, "The Use of 68 Ga-PSMA PET CT in Men with Biochemical Recurrence After Definitive Treatment of Acinar Prostate Cancer" and "Initial multicentre experience of 68Gallium PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited" in British Journal of Urology International. He was involved in the successful Wesley Research Institute's attainment of The Australian Cancer (ACRF) Cancer Research Facility grant in 2009 and most recently in 2017, ARC ITTC (Australian Research Council Industrial Transformation Training Centre with the University Queensland's Centre of Advanced Imaging.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats
His awards have included the Rouse Travelling Fellowship, ANZSNR Symposium Neuroradiologicum Award, Schering Anniversary Research Grant, Philips Medical Prize, Brian Smith Memorial Award, Siemens Medical Solutions Prize, GE Medical Systems Research Prize, Amersham Poster Prize ANZAPNM Registrar Award, Johnson and Johnson Medical Educational Bursary and Princess Alexandra Hospital Private Practice Research and Education Trust Fund Scholarship.

You Must Be Logged In To Post A Comment

 

advertisement

Molecular Imaging Homepage

EXPLORER scanner cuts total-body PET imaging time for cancer detection to 20 minutes
Uses a variation of the Patlak plot — called the relative Patlak plot — to generate high-quality parametric images
OEMs dominate PET/CT service landscape, IMV reports
Among midsized hospitals, OEM support stood at 77%, with 20% in-house and 13% ISO
IBA debuts compact synthesizer for radiopharmaceutical manufacturing
CASSY is designed to integrate into existing lab workflows and optimize space within hot cells
Ratio Therapeutics plans radiopharmaceutical manufacturing site in Salt Lake City
Designed for end-to-end production of radiopharmaceuticals, with an eye toward scaling up for commercial supply
SHINE Technologies to acquire Lantheus’ SPECT division
Deal includes the manufacturing operations at Lantheus’ North Billerica, Massachusetts site
Blue Earth Therapeutics begins phase 2 trial of lutetium-based radioligand for prostate cancer
Assessing efficacy and safety across different dosing regimens
SpectronRx passes FDA inspection with no observations for Indianapolis facility
Plans to expand operations to meet global demand for radiopharmaceuticals
SHINE enters UAE market with Modawina partnership for Lu-177 distribution
Extends presence across the Europe, Middle East, and Africa regions
PET procedure volumes in US rose 12% in 2024
Demand grew alongside limited expansion in installed imaging capacity, according to IMV
SHINE and Sumitomo form partnership to expand radioisotope supply in Asia
The agreement will focus on establishing supply chains for SHINE’s core offerings